期刊文献+

TX和TC新辅助化疗Ⅱ、Ⅲ期乳腺癌患者的疗效比较 被引量:5

下载PDF
导出
摘要 目的:比较多西他赛+卡培他滨(TX)和多西他赛+卡铂(TC)新辅助化疗Ⅱ、Ⅲ期乳腺癌患者的近期疗效和毒副反应。方法:将47例Ⅱ、Ⅲ期乳腺癌患者随机分为两组,TX组20例接受TX方案和TC组27例接受TC方案化疗,21d为1个周期,两组患者均完成了4个周期的化疗,观察和比较4个周期新辅助化疗后两组的近期疗效和毒副反应。结果:TX组和TC组的总有效率分别为55.0%(11/20)和66.7%(18/27),两组比较差异无统计学意义(P=0.250)。两组患者主要不良反应均为贫血、中性粒细胞和血小板减少、脱发、恶心及呕吐、肝功能异常和疲劳,两组比较差异无统计学意义(P>0.05)。但TX组患者出现手—足综合征、皮肤色素沉着、口腔黏膜炎和指甲变黑或脱落,在TC组并未出现。结论:TC与TX的4个周期新辅助化疗Ⅱ、Ⅲ期乳腺癌患者近期疗效相当,不良反应相似,但TX方案手—足综合征和全身色素沉着常见。
出处 《广西医科大学学报》 CAS 2016年第2期283-285,共3页 Journal of Guangxi Medical University
基金 广西医疗卫生适宜技术研究与开发课题资助项目(No.S201415-03)
  • 相关文献

参考文献12

  • 1Yoo C,Kim SB,Ahn JH,et al. A randomized phase II trial of capecitabine plus vinorelbine followed by do- cetaxel versus adriamycin plus cyclophosphamide fol- lowed by docetaxel as neoadjuvant chemotherapy for breast cancer[J]. Cancer Research & Treatment,2014, 47(3) :406 -415.
  • 2Eisenhauer EA, Therasse P, Bogaerts J, et al. New re sponse evaluation criteria in solid turnouts: reviscd RE- CIST guideline (version 1. 1)[J]. European Journal of Cancer,2009,45(2) :228-247.
  • 3皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144. 被引量:524
  • 4Abedi M,Farrokh D,Shandiz HF,et al. The Validity of MRI in Evaluation of Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer[J]. I- ranian Journal of Cancer Prevention,2013,6(1) :28-35.
  • 5蒋奕,叶新青,黄俊淇,韦常宏,叶洪涛.乳腺癌新辅助化疗前后分子标记物变化及其与疗效的关系[J].广西医科大学学报,2015,32(2):211-215. 被引量:12
  • 6Chang HR, Glaspy J, Allison MA, et al. Differential re- sponse of triple negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment[J]. Canc er,2010,116(18):4227-4237.
  • 7Babyshkina N, Malinovskaya E, Patalyak S, et al. Neo adjuvant chemotherapy for different molecular breast cancer subtypes:a retrospective study in Russian popu- lation[J]. Medical Oncology,2014,31(9) :1-12.
  • 8Jeong J H,Jung SY, Park IH, et al. Predictive factors of pathologic complete response and clinical tumor pro- gression after preoperative chemotherapy in patients with stage II and III breast cancer[J]. Investigational New Drugs,2010,30(1) :408-416.
  • 9Zhang M, Qiu JN,Qu SX,et al. The clinical observation of neoadjuvant chemotherapy in locally advanced breast cancer with DX regimen[J]. Revista Peruana De Medic- ina Experimental Y Salud Pfiblica, 2014,30 ( 11 ) : 515 -517.
  • 10Lee KS, Ro J, Nam BH,et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cy clophosphamide as primary chemotherapy for patients with stage II/III breast cancer[J]. Breast Cancer Re- search & Treatment,2008,109(3) :481-489.

二级参考文献21

  • 1张斌,张强,赵林,龙飞,李爽,姜大庆,徐宏.乳腺癌新辅助化疗疗效的评价及影响因素分析[J].中华肿瘤杂志,2006,28(11):867-870. 被引量:44
  • 2卜擎燕,熊宁宁,邹建东,蒋萌,刘芳,Anna Zhao-Wong.ICH国际医学用语词典(MedDRA):药事管理的标准医学术语集[J].中国临床药理学与治疗学,2007,12(5):586-590. 被引量:39
  • 3Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Nail Cancer Inst Monogr,2001,30 :96-102.
  • 4von Minekwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol, 2005, 16:56-63.
  • 5Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oneol, 2007,18 : 1927-1934.
  • 6Rcitsamer R, Peintinger F, Prokop E, et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxoruvicin and docetaxel in the neoadjuvant setting of patients with stage Ⅱand Ⅲ breast cancer. Anticancer Drugs, 2005.16:867-870.
  • 7Rajah R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer,2004,5:235-238.
  • 8Iwase S, Yamamoto D, Kuroda Y, et al. Phase II Trial of Preoperative Chemotherapy for Breast Cancer: Japan Breast Cancer Research Network (JBCRN) -02 TriM. Anticancer Res, 2011,31 : 1483-1487.
  • 9Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clln Cancer Res ,2005,11:5678-5685.
  • 10Ogston KN,Miller ID,Payne S, et al. A new histologi- cal grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast,2003,12(5) : 320-327.

共引文献539

同被引文献67

引证文献5

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部